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Abstract
The aim of the present study was to test the hypothesis that the cardiovascular-protective effects of eicosapentaenoic acid
(EPA) may be due, in part, to its ability to stimulate the AMP-activated protein kinase (AMPK)-induced endothelial nitric
oxide synthase (eNOS) activation. The role of AMPK in EPA-induced eNOS phosphorylation was investigated in bovine aortic
endothelial cells (BAEC), in mice deficient of either AMPKa1 or AMPKa2, in eNOS knockout (KO) mice, or in Apo-E/AMPKa1
dual KO mice. EPA-treatment of BAEC increased both AMPK-Thr172 phosphorylation and AMPK activity, which was
accompanied by increased eNOS phosphorylation, NO release, and upregulation of mitochondrial uncoupling protein-2
(UCP-2). Pharmacologic or genetic inhibition of AMPK abolished EPA-enhanced NO release and eNOS phosphorylation in
HUVEC. This effect of EPA was absent in the aortas isolated from either eNOS KO mice or AMPKa1 KO mice fed a high-fat,
high-cholesterol (HFHC) diet. EPA via upregulation of UCP-2 activates AMPKa1 resulting in increased eNOS phosphorylation
and consequent improvement of endothelial function in vivo.
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Introduction
Eicosapentaenoic acid (20:5Delta (5,8,11,14,17); v-3: EPA) is an
v-3 polyunsaturated fatty acid (PUFA), which is abundant in fish
oils. Epidemiological and clinical trials have shown that v-3 fatty
acids, in particular EPA, reduce cardiovascular deaths [1] and
retard the progression of atherosclerosis in coronary patients [2].
The precise mechanism by which fish oils inhibit atherosclerosis is
still unclear, but it may relate to the modulation of lipid
metabolism [3], improvement of vascular endothelial function
[4], enhancement of vascular reactivity and compliance [5],
reduction of cytokine production [6], and inhibition of inflamma-
tory processes [7].
Nitric oxide (NO) is essential for endothelial function.
Decreased NO bioactivity is involved in the pathogenesis of many
cardiovascular disorders such as hypertension, atherosclerosis,
venous bypass graft disease, diabetic vascular disease [8]. There is
evidence that the beneficial effects of EPA may be due to its ability
to augment levels of NO. In diabetic rats, long term oral
administration of EPA may stimulate NO production, and
increased NO levels likely inhibit enhanced cardiac sympathetic
activity in these animals [9]. Similarly, the n-3 fatty acids promote
the synthesis of beneficial NO in the endothelium [10]. In rabbits,
EPA reduces myocardial infarct size, primarily through calcium
channel–mediated mechanisms and partially through NO-medi-
ated mechanisms [11]. Accumulating evidence shows that v-3
PUFA can regulate NOS activity and increase NO synthesis in
endothelial cells and vascular smooth muscle cells [12,13].
However, the mechanisms underlying v-3 PUFA-enhanced NO
release remain poorly understood.
The AMP-activated protein kinase (AMPK) is a heterotrimeric
protein composed of a, b, and c subunits. The a subunit imparts
catalytic activity, while the b subunit contains a glycogen-binding
domain (GBD) that also regulates the activity and the c subunit
forms the broad base of the protein and is required for AMP
binding [14,15]. AMPK is well-conserved among eukaryotic cells
and is expressed by endothelial cells of different origins [16,17,18].
Activation of AMPK requires phosphorylation of Thr172 in the
activation loop of the a subunit [19] and is mediated by at least
two kinases, Peutz-Jeghers syndrome kinase LKB1 [20] and Ca
2+/
calmodulin-dependent protein kinase kinase (CaMKK) [21].
AMPK has been shown to mediate angiogenic and anti-
inflammatory effects, which are thought to be due to NO
formation [17,22,23,24]. AMPK is reported to phosphorylate
endothelial nitric oxide synthase (eNOS) at Ser1177 or 1179
[17,22] and enhance the interaction between eNOS and heat
shock protein 90 [25]. Based on these reports, we hypothesized
that the protective effects of EPA on the cardiovascular system
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induced eNOS activation and consequently, NO production.
Here, we provide evidence of a novel pathway in which EPA
activates AMPK in endothelial cells through an upregulation of
UCP-2.
Results
EPA induces AMPK phosphorylation and activation
To investigate whether EPA activates AMPK in endothelial
cells, confluent BAEC or HUVEC were treated with varying
concentrations of EPA for 2 to 24 h. AMPK activation was
indirectly assessed by western blot analysis of AMPK phosphor-
ylation at Thr172, which is essential for AMPK activity [26].
Ser79 phosphorylation of ACC, a substrate of AMPK [27], was
also used as an indicator of AMPK activation. As shown in
Figure 1A, the phosphorylation of both AMPK and ACC
gradually increased beginning from 6 h after incubation with
25 mM of EPA and reached peak levels at 24 h in BAEC.
Increased AMPK phosphorylation was associated with elevated
AMPK activity, as measured by the SAMS peptide assay
(Figure 1C). EPA treatment did not alter total levels of AMPK
and ACC, suggesting that EPA-induced phosphorylation of
AMPK and ACC was not due to altered expression of these
proteins. Since EPA activated AMPK in both BAEC and HUVEC
at similar potency (data not shown), we performed most of the
experiments in BAEC.
We next examined the dose-dependent effects of EPA on
AMPK-Thr172 and ACC-Ser79 phosphorylation. EPA did not
affect phosphorylation of AMPK or ACC at a concentration of
5 mM (Figure 1B). In contrast, EPA at 25 mM significantly
enhanced AMPK phosphorylation (Figure 1B). Increasing con-
centrations of EPA (50 and 100 mM) further enhanced AMPK
phosphorylation. The changes in ACC phosphorylation mirrored
those of AMPK. Levels of total AMPK and ACC remained
unchanged at all EPA concentrations tested. Based on these
results, 25 mM appears to be the lowest effective concentration of
EPA. Thus, BAEC were stimulated with 25 mM EPA for 24 h in
subsequent experiments.
EPA-induced eNOS phosphorylation is AMPK-dependent
We had previously demonstrated that AMPK phosphorylates
and activates endothelial nitric oxide synthase (eNOS) in cultured
endothelial cells [23]. Similarly, Zhang et al. [28] demonstrated
that infection of endothelial cells with a recombinant adenovirus
expressing the constitutively active AMPK results in eNOS
activation and increased NO production. Treatment of BAEC
with EPA increased eNOS-Ser1179 phosphorylation, with the
time-course of phosphorylation being very similar to that for
AMPK phosphorylation (Figure 2A). The dose-dependent effects
of EPA on eNOS phosphorylation were also similar to those for
AMPK phosphorylation (Figure 2B). Given that EPA activates
both AMPK and eNOS in BAEC, we then investigated whether
the EPA-stimulated eNOS phosphorylation involves AMPK by
infecting BAEC with adenovirus encoding dominant negative
AMPK (Ad-DN-AMPK). As expected, treatment of control BAEC
(Ad-GFP-infected or non-infected BAEC) with 25 mM EPA for
24 h elicited increased phosphorylation of both AMPK and eNOS
(Figure 2C). In contrast, overexpression of Ad-DN-AMPK
Figure 1. EPA activates AMPK in BAEC. BAEC were treated with (A)2 5mmol/L EPA for the indicated times or (B) varying concentrations of EPA
for 24 h. Lysates (80 mg) were analyzed by western blot for the indicated proteins. The blot is a representative of four blots obtained from four
separate experiments. Corresponding densitometric analyses of phosphorylated AMPK and ACC are shown. *, P,0.05 vs. control groups. C) Confluent
BAECs were treated with vehicle or EPA (25 mmol/L) for 24 hours. AMPK activity was assayed using the SAMS peptide as a substrate. Data presented
are means 6 SD from 3 independent experiments. P,0.05 vs. vehicle.
doi:10.1371/journal.pone.0035508.g001
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Ser1177 in human) phosphorylation.
Both Akt and AMPK are capable of phosphorylating eNOS at
Ser1179 [29], prompting us to determine whether Akt may also
contribute to EPA-enhanced eNOS phosphorylation. As shown in
Figure 2D, EPA did not increase basal Akt phosphorylation at
Ser473, suggesting that EPA-stimulated eNOS phosphorylation
does not require Akt but depends on activation of AMPK.
EPA-enhanced NO production is AMPK-dependent
Next, we determined if EPA-induced eNOS phosphorylation is
associated with increased NO release. EPA significantly increased
NO release, which was inhibited by L-NAME, a non-selective
inhibitor of NOS (Figure 2E). In addition, inhibition of AMPK
with compound C or through infection with Ad-DN-AMPK
ablated EPA-enhanced NO release (Figure 2E and F). Important-
ly, both treatments reduced AMPK activity in EPA-treated cells to
below control levels (Figure 2E and F).
UCP-2 is required for EPA-induced AMPK
phosphorylation
AMPK is activated by an increase in the AMP/ATP ratios and
by ATP depletion [30]. Because intracellular ATP production rests
mainly on mitochondrial DY [31], we tested the effect of EPA on
the expression of the mitochondrial proton carrier, uncoupling
protein 2 (UCP-2). UCP-2 levels were quantified in BAEC treated
with 25 mM of EPA for up to 24 h. The increase in UCP-2 protein
occurred by 5.5 h and appeared to reach a plateau by 24 h
(Figure 3A).
We next determined if genetic inhibition of UCP-2 altered EPA-
induced AMPK activation. Since siRNA for bovine UCP-2 was
not available, we performed these experiments in HUVEC. As
shown in Figure 3B, transfection of UCP-2 siRNA but not
scrambled siRNA markedly reduced the basal levels of UCP-2 in
HUVEC, implying that HUVEC expressed detectable levels of
UCP-2 sensitive to UCP-2-specific siRNA. Moreover, transfection
of UCP-2-specific siRNA but not scrambled siRNA significantly
Figure 2. AMPK mediates EPA-induced eNOS phosphorylation and NO production in BAEC. BAEC were treated with (A) EPA 25 mmol/L
for the indicated times or (B) varying concentrations of EPA for 24 h. Lysates were analyzed by western blot for the indicated proteins. The blot is a
representative of four blots obtained from four separate experiments. C) Western blot of phosphorylated AMPK and eNOS in EPA-stimulated BAEC
infected with adenoviruses encoding GFP or Ad-DN-AMPK. D) Phosphorylation of Akt in EPA-stimulated BAEC. The data in C and D represent results
of 3 separate experiments. For A–D, corresponding densitometric analyses are shown. *P,0.05 vs. control. E) NO release in EPA-stimulated BAEC.
BAEC were treated with compound C (AMPK inhibitor) (20 mmol/L), DMSO (vehicle), or L-NAME (NOS inhibitor) (0.1 mM) for 30 min prior to
stimulation with EPA. n=4 for each treatment group. *P,0.05 vs. control;
#P,0.05 vs. EPA. F) NO release by EPA-stimulated BAEC infected with Ad-
DN-AMPK (50 multiplicities of infection) or Ad-GFP (control). *P,0.05 vs. non EPA-treated, Ad-GFP group;
#P,0.05 vs. EPA-treated, Ad-GFP group. For
A and B, the corresponding AMPK activity is shown in the lower panel.
doi:10.1371/journal.pone.0035508.g002
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Consistent with these results, siRNA-mediated knockdown of
UCP-2 abolished EPA-enhanced AMPK phosphorylation, while
scrambled siRNA had no effect (Figure 3C). Further, infection of
BAEC with adenovirus encoding constitutively active UCP-2 (Ad-
CA-UCP-2) significantly increased AMPK phosphorylation
(Figure 3C), indicating that UCP-2 expression was able to activate
AMPK in BAEC. On the other hand, and infection of HUVEC
with Ad-DN-AMPK did not alter EPA-induced UCP-2 upregula-
tion (Figure 3D). These data indicate that UCP-2 might be
required for EPA-induced AMPK activation in endothelial cells.
Because AMPK is highly sensitive to small changes in the
intracellular ATP/ADP ratio [14], we explored whether EPA
induces alterations in ATP/ADP through upregulation of UCP-2.
To test this possibility, HUVEC were transfected with UCP-2
siRNA or control siRNA, then treated with 25 mM EPA for 24 h.
Some HUVEC were co-transfected with Ad-DN-AMPK (or with
Ad-GFP as a control) to account for slight changes in intracellular
ATP levels due to AMPK activation. We found that EPA
significantly decreased intracellular ATP/ADP and that UCP-2-
specific siRNA blocked this effect in both Ad-DN-AMPK-
transfected HUVEC and untransfected HUVEC (Figure 3E).
Thus, reductions in cellular ATP levels by EPA may contribute to
AMPK activation.
EPA stimulates UCP-2 expression partly via a PPARc-
mediated pathway
Thiazolidinediones, which are potent peroxisome proliferator-
activated receptor-c (PPARc) agonists, have been shown to
increase expression of UCP-2 in several tissues [32], leading to
the proposal that PPARc mediates changes in UCP-2 expression
[33]. To test whether PPARc was required for EPA-induced
UCP-2 expression, we compared UCP-2 expression among BAEC
Figure 3. EPA induces AMPK phosphorylation through UCP-2-dependent ATP inhibition. A) Time course of EPA upregulation of UCP-2.
BAEC were incubated with 25 mM EPA for various amounts of time. After the appropriate incubation time, cells were lysed and UCP-2 protein levels
were measured as described. n=4, *P,0.05; **P,0.01 vs. 0 h time point. B) UCP-2 siRNA significantly suppressed basal UCP-2 protein levels. HUVEC
were incubated with UCP-2-specific siRNA, scrambled siRNA, EPA and its vehicle BSA for 24 h followed by analysis of UCP-2 protein levels. C) Western
blot analysis of AMPK and UCP-2 in EPA-stimulated HUVEC. HUVECs were pretreated with UCP-2-specific siRNA (1 mg/30-mm dish), scrambled siRNA,
or siRNA transfection reagent. Alternatively, a subset was infected with Ad-CA-UCP-2 or Ad-GFP (control) prior to stimulation. The blot is a
representative of four blots obtained from four separate experiments. D) Western blot analysis of UCP-2 in EPA-stimulated HUVEC infected with Ad-
DN-AMPK (50 multiplicities of infection). Cells left non-infected (non-ad) or infected with Ad-GFP served as controls. The data represent results of
three separate experiments. For C and D, corresponding densitometric analyses are shown. E) Intracellular ATP/ADP ratio in EPA-stimulated cultures
pretreated with scrambled or UCP-2-specific siRNA. Results are expressed as mean 6 SD from three independent experiments conducted in triplicate.
*P,0.05; **P,0.01 vs. control;
#P,0.05 vs. EPA/scrambled siRNA.
doi:10.1371/journal.pone.0035508.g003
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zone, a PPARc agonist, elicited a large increase in UCP-2 protein
levels (,5.2-fold, P,0.05). This increase was of a slightly greater
magnitude to that seen with EPA (Figure 4A). The other PPARa
agonist, Wy14643, resulted in a moderate increase in UCP-2 levels
(,1.5-fold, P,0.05). Treatment of BAEC with GW9662, an
antagonist of PPARc, partially abrogated the stimulatory effect of
EPA on UCP-2 protein expression (Figure 4B), while the PPARa
antagonist MK-886 had no effect on UCP-2 expression. These
data suggest that EPA-induced upregulation of UCP-2 may be
mediated, in part, by PPARc.
To further verify that EPA increases endothelial UCP-2
expression and AMPK activation through PPARc-dependent
signaling, HUVEC were transfected with PPARc-specific siRNA
and assayed for PPARc expression, UCP-2 expression, and
AMPK phosphorylation in the presence of EPA. Western blotting
verified that PPARc expression was selectively and significantly
reduced by the cognate PPARc siRNA duplex compared with
scrambled siRNA (Figure 4C). Importantly, PPARc siRNA-
transfected cells displayed a significant reduction in EPA-induced
UCP-2 expression and AMPK phosphorylation compared with
mock-transfected cells (Figure 4C).
EPA induces UCP-2 expression and AMPK a1-mediated
eNOS phosphorylation in vivo
To determine whether EPA activates AMPK in vasculature,
C57BL/6J mice were given EPA (500 mg/kg/d in drinking water)
for 4 months, and aortic levels of AMPK, ACC, and eNOS
phosphorylation and UCP-2 protein expression were determined.
As shown in Figure 5A, levels of Thr172-phosphorylated AMPK
were significantly increased in EPA-treated animals. The phos-
phorylation of ACC and eNOS was also elevated to a similar
degree as that for AMPK.
We also investigated if AMPK mediates the effects of EPA in an
isoform-specific manner. As demonstrated in Figure 5B, admin-
istration of EPA for 4 months significantly increased the levels of
Ser1177-phosphorylated eNOS in aortas from WT and AMPKa2
KO mice. However, EPA activation of eNOS phosphorylation
was not observed in AMPKa1 KO animals, indicating that EPA-
induced eNOS phosphorylation is mainly mediated by AMPK a1.
Role of AMPK in EPA-enhanced endothelium-dependent
vasorelaxation in Apo-E
2/2 mice aortas
Next, to investigate the role of AMPK in endothelial function,
we tested the effect of EPA, AICAR, and compound C on
endothelium-dependent vasoreactivity under ex-vivo conditions.
Acetylcholine (Ach) induced concentration-dependent arterial
vasodilatation in all groups (Figure 6A). Ach-induced vasodilata-
tion was markedly attenuated in Apo-E KO mice, with the
maximum relaxation response of arteries being 44.265.4% and
that from wild type mice being 85.6610.5% (n=4 per group,
P,0.01). It should be noted that, following treatment with AICAR
or EPA, Ach-induced vasodilatation in aortas from Apo-E KO
mice was significantly improved. In contrast, inhibition of AMPK
with compound C abolished EPA-stimulated increases in Ach-
induced relaxation in this group, where the maximal relaxation
was 76.465.5% for EPA alone and 52.967.3% in the presence of
compound C (Figure 6A). These data suggest that AMPK might
play an important role in enhanced endothelial function elicited by
EPA.
To further substantiate the role of AMPKa1 in EPA-induced
improvement in endothelium function, we assayed the effects of
EPA in endothelium -dependent and –independent vasorelaxation
in aortas isolated from Apo-E or Apo E/AMPKa1 dual KO mice.
As illustrated in Figure 6B, the endothelium-dependent relaxation
in response to Ach was significantly reduced in the aortas of Apo-
Figure 4. EPA stimulates UCP-2 expression via a PPARc-mediated pathway in BAEC. A, B) Western blot analysis of UCP-2 in EPA-
stimulated BAEC pretreated with 10 mmol/L Wy14643 (PPARa agonist), 10 mmol/L rosiglitazone (PPARc agonist), 10 mmol/L MK886 (PPARa
antagonist), or 10 mmol/L GW9662 (PPARc antagonist). *P,0.05 vs. control; **P,0.01 vs. control;
#P,0.05 vs. EPA. C) Western blot analysis of AMPK,
UCP-2, and PPARc in EPA-stimulated HUVEC transfected with PPARc siRNA or scrambled siRNA for 48 h. *P,0.05 vs. control;
#P,0.05 vs. scrambled
siRNA + EPA. For A–C, the blot is a representative of four blots obtained from four separate experiments, and the corresponding densitometric
analyses are shown.
doi:10.1371/journal.pone.0035508.g004
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PLoS ONE | www.plosone.org 5 April 2012 | Volume 7 | Issue 4 | e35508Figure 5. EPA upregulates UCP-2 and activates AMPK in mice. A) Western blot analysis of phosphorylated AMPK, ACC, and eNOS in the
thoracic aorta of mice receiving EPA or DMSO (vehicle) in their drinking water for 16 weeks (n=3 for each group). Corresponding densitometric
analyses are shown. *P,0.05 vs. control. B) Western blot analysis of eNOS phosphorylation in wild type (WT), AMPKa1 knock out (KO), and AMPKa2
KO mice receiving EPA for 16 weeks (n=3 for each group). The relative p-eNOS/eNOS ratios are shown. *P,0.05 vs. non-treated WT;
#P,0.05 vs. EPA-
treated WT. *P,0.05 vs. control; **P,0.01 vs. control.
doi:10.1371/journal.pone.0035508.g005
Figure 6. Both AMPK a1 and NO are required for EPA-enhanced endothelium-dependent vasodilatation in ex vivo or in vivo.A )
Endothelium-dependent relaxation of the aortic rings in response to acetylcholine (Ach) from wild type or Apo-E
2/2 mice. Aortic rings were
pretreated 6 compound C, then incubated with EPA or AICAR (n=4 for each group). Each data point represents relaxation expressed as a percentage
of the value obtained for phenylephrine-preconstricted aorta. *P,0.05 vs. wild type; **P,0.01 vs. wild type;
#P,0.05 vs. Apo-E
2/2; P,0.05 vs. Apo-
E
2/2 + EPA. B) AMPKa1 and eNOS are required for EPA-induced amelioration of endothelium function. Aortic rings extracted from Apo-E KO, Apo-E/
AMPKa1 dual KO or eNOS KO mice were incubated with or without EPA (25 mM) for 24 h in EBM. The endothelium-dependent relaxation were
assayed by the addition of acetylcholine at concentrations indicated (n=4 for each group). *P,0.05; **P,0.01 vs. Apo-E
2/2 mice.
doi:10.1371/journal.pone.0035508.g006
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KO mice. Further, EPA significantly increased Ach-induced
endothelium-dependent relaxation in Apo-E KO but not in the
aortas from Apo-E/AMPKa1 dual KO mice (Figure 6B),
suggesting that AMPKa1 was required for EPA-enhanced
endothelium-dependent vasorelaxation ex vivo.
To further determine the contribution of eNOS in EPA-
enhanced relaxation, we next determined the effect of EPA in the
aortas from eNOS KO mice. As expected, endothelium-
dependent relaxation in response to Ach was minimal
(Figure 6B). In addition, EPA at 25 mM did not alter Ach-induced
relaxation in the aortas from eNOS KO mice. As endothelium-
independent vasorelaxation caused by sodium nitroprusside were
similar among Apo-E KO, eNOS KO, and Apo-E/AMPK a1
KO (data not shown). Overall, our results implied that eNOS was
required for EPA-enhanced endothelium-dependent relaxation at
the doses tested.
Discussion
AMPK is activated by a rise in AMP and a decrease in ATP,
both of which occur by inhibiting ATP production or accelerating
ATP consumption [14]. The uncoupling proteins (UCP1, UCP-2,
and UCP3) are mitochondrial transporters that are capable of
dissipating the proton gradient and increasing thermogenesis,
while reducing the efficiency of ATP synthesis [34]. Since AMPK
is potently stimulated by depletion of intracellular ATP (or
increased AMP:ATP) resulting from the upregulation of UCP-2 in
target tissues [35], a possible functional link between these two
intracellular systems has emerged. In the present study, we have
for the first time provided evidence that EPA via UCP-2
expression increases NO release and endothelial function via
AMPK activation in vivo. The beneficial effects of EPA appear
independent of serum lipids and EPA via AMPK activation exerts
a direct vasoprotective effect. Furthermore, we have characterized
that UCP-2 mediates AMPK responses to EPA in endothelial cells.
Indeed, our data reveal that EPA significantly increases UCP-2
protein expression and AMPK phosphorylation both in vitro and in
vivo. The upregulation of UCP-2 by EPA is consistent with the
findings reported by Armstrong et al. [36] Moreover, all classes of
unsaturated FFA and/or their metabolites have been shown to
upregulate UCP-2 mRNA in cultured cells [37,38]. Indeed,
siRNA-mediated knockdown of UCP-2 protein blocked EPA
stimulation of AMPK phosphorylation, and overexpression of
UCP-2 directly increased AMPK phosphorylation. These findings
support a role for UCP-2 in EPA-induced activation of AMPK.
The mechanism by which EPA increases UCP-2 expression
remains unclear. We observed a significant increase in UCP-2
expression after exposure to EPA or PPARc agonist (rosiglitazone),
while only modest increases in UCP-2 expression were observed
with the PPARa agonist (Wy14643). The PPARc antagonist
(GW9662) but not the PPARa antagonist (MK-886) significantly
blocked EPA-induced upregulation of UCP-2. These results could
be further substantiated using specific PPARc siRNA. Together,
these data suggest that EPA induction of UCP-2 expression was
mediated partly by PPARc.
Another important observation of the present study is that
chronic EPA supplementation significantly increased eNOS
Ser1177 phosphorylation, NO release, and Ach-induced endothe-
lium-dependent relaxation. Further, we have provided evidence
that AMPK was required for increased NO bioactivity. Finally, we
have shown that AMPK might have direct vaso-protective effects
as EPA supplementation improves endothelial function without
altering lipids in serum. Our results strongly imply that a direct
activation of AMPK in endothelial cells might have broad
physiological effects, leading to improvement of endothelial
function. In addition to activating eNOS, activated AMPK
increases fatty acid oxidation by phosphorylating and inhibiting
ACC, which serves to decrease the concentrations of malonyl-CoA
[39]. Decreased malonyl-CoA could, in turn, inhibit the
accumulation of lipids associated with endothelial dysfunction,
which is the precursor of atherosclerosis [40]. Activation of AMPK
also decreases fatty acid incorporation into glycerolipids, either
secondary to its effect on fatty acid oxidation or through its ability
to phosphorylate and inhibit sn-glycerophosphate acyltransferase,
the first committed enzyme in diacylglycerol and triglyceride
synthesis [41]. An additional benefit of endothelial AMPK activity
is that it may inhibit glycerol-3-phosphate acyltransferase, which is
required for the de novo synthesis of diacylglycerol [41]. In this way,
AMPK may lessen endothelial diacylglycerol production (and thus
PKC activation) by diminishing availability of the FFA substrate
for its synthesis and by directly inhibiting the enzyme which
catalyzes its synthesis. The importance of AMPK in the
development of endothelial dysfunction and atherosclerosis is best
demonstrated by recent studies showing that metformin, one of the
most used anti-diabetic drugs which was recently to exert its
therapeutic effect in diabetes by activating AMPK [42,43], has
been shown to improve vascular functions and to dramatically
reduce cardiovascular endpoints and mortality for type II diabetic
patients in large scale clinical trials [44,45,46].
In summary, we have uncovered a novel pathway by which the
v-3 fatty acid EPA activates AMPK in endothelial cells. This
pathway, which relies on UCP-2 as a mediator of AMPK
activation, stimulates NO production through eNOS phosphory-
lation. Thus, AMPK activation may help account for the




Bovine aortic endothelial cells (BAEC) and cell culture media
were obtained from Clonetics Inc. (Walkersville, MD). Human
umbilical vein endothelial cells (HUVEC) and cell culture media
were purchased from Cascade Biologics (Portland, OR). FFA-free
bovine serum albumin (BSA), palmitic acid, oleic acid, GW9662,
and MK-886 were obtained from Sigma (St. Louis, MO).
Wy14643 and rosiglitazone were obtained from Cayman Chem-
ical Co. (Ann Arbor, Michigan, USA), and 5-aminoimidazole-4-
carboxamide-1-b-D-ribofuranoside (AICAR) was purchased from
Toronto Research Chemicals, Inc (Toronto, Canada). Antibodies
against phospho-acetyl-CoA carboxylase (ACC) (Ser79), phospho-
AMPK (Thr172), AMPK, and phospho-eNOS (Ser1177) were
purchased from Cell Signaling Inc. (Beverly, MA). The antibodies
against ACC were obtained from Alpha Diagnostic International,
Inc. (San Antonio, TX). All other chemicals and organic solvents
were of the highest grade and were obtained from Sigma.
Animals
To generate Apo-E/AMPK dual knockout (KO) mice, Apo-E
KO mice obtained from Jackson Labs were crossbred for at least 5
generation with the mice deficient of AMPK a1. Deficiency of
both Apo-E and AMPK a1 was confirmed by both RT-PCR and
western blots by using the specific antibody against AMPK a1. As
both AMPK KO mice and Apo-E KO had extensively been
backcrossed to the C57BL6 background, C57BL6 mice aged 8-
months were used as wild type control (WT) in the study. All
animal protocols were approved by the Institutional Animal Care
Eicosapentaenoic Acid Activates AMPK
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Center.
Cell culture, addition of EPA and adenoviral infection
BAEC were grown in EBM supplemented with 2% fetal bovine
serum (FBS). HUVEC were maintained in Medium 200
supplemented with a low serum growth supplement (LSGS) before
use. All culture media were supplemented with both penicillin (100
Units/ml) and streptomycin (100 mg/ml). Cells between passages 5
and 10 were used for all experiments. All cells were incubated in a
humidified atmosphere of 5% CO2/95% air at 37uC. The fatty
acids were added to the cell cultures coupled to fatty acid-free BSA
in the ratio of 2 mol of fatty acid to 1 mol of albumin [47]. When
the ECs were 90% confluent, the maintenance medium was
removed and cells were treated with EPA (0 to 100 mmol/L), in
medium with 2% FCS for 0 to 24 h. In other studies, BAEC or
HUVEC were infected with adenoviruses encoding green
fluorescence protein (GFP) as a control (Ad-GFP), constitutively
active human UCP2 (Ad-CA-UCP2), or a dominant negative
mutant form of AMPK alpha (Ad-DN-AMPK). The AMPK-DN
adenoviral vector was constructed from AMPK bearing a
mutation altering lysine 45 to arginine (K45R) as described
previously [42,48]. Infection was performed in 80% confluent
cultures with media containing 0.1% FCS and recombinant
adenovirus at a multiplicity of infection of 50. Cells were further
incubated with EBM for additional 24 h (HUVEC) or 48 h
(BAEC) before experimentation. Using these conditions, infection
efficiency was typically at least 80%, as determined by GFP
expression.
SiRNA silencing of PPARc or UCP2 in HUVEC
HUVEC (passages 3–5) were grown in antibiotic free-EGM-2
medium containing 2% FBS until 70% confluence and transfected
with human-specific PPARc siRNA, UCP2 siRNA, or corre-
sponding scrambled siRNA for 48 h using Lipofectamine
TM 2000
(Invitrogen) according to the manufacturer’s instructions. The final
concentration of siRNA was 200 nM.
Measurement of nitric oxide production
For NO detection, BAEC grown in 24-well plates were
incubated for 30 min in the presence of 15 mM 4,5-diaminofluor-
escein diacetate (DAF-2 DA) in PBS or in PBS alone (control) in
the dark at 37uC. Cells were then washed with PBS to remove
excessive DAF-2 DA, and the change in fluorescence was recorded
for 15 min at room temperature using a microplate reader (FL
600, Bio-Tek) with the excitation wavelength set at 485 nm and
the emission wavelength set at 530 nm. Changes in fluorescence
were also visualized with a fluorescence microscope (Olympus
IX71), and images were captured for analysis [49].
Determination of adenine nucleotides
HUVEC were cultured in 6-well plates with control siRNA or
UCP2 siRNA for 48 h, treated with EPA or vehicle for 24 h,
washed with PBS, and scraped in 0.3 ml of PBS. ATP and ADP
were then measured in quadruplicate by a luminometric method
as described elsewhere [50].
Western blot analysis
BAEC or HUVEC and thawed mouse aortas were lysed in cold
RIPA buffer. Protein concentrations were determined with a
bicinchoninic acid (BCA) protein assay system (Pierce, Rockford,
IL). Proteins were subjected to Western blots using ECL-Plus, as
described previously [42]. Relative PPARc protein expression was
measured in nuclear extracts from HUVEC as previously detailed
[51]. The intensity (area6density) of the individual bands on
Western blots was measured by densitometry (model GS-700,
Imaging Densitometer; Bio-Rad). The background was subtracted
from the calculated area.
AMPK activity assay
AMPK activity was assayed using the SAMS peptide, as
previously described [48]. The activity was determined in the
presence and absence of AMP (200 mM). AMPK activity was
calculated by determining the difference in activity between both
conditions.
Measurement of endothelium-dependent and
endothelium-independent vasorelaxation
Aortic rings (3–4 mm in length) extracted from C57BL6 aged 8-
weeks, 20-weeks, 4-months or 8-months (wild type, WT), Apo-E
KO aged 8-months, Apo-E/AMPK dual KO mice (8-month old)
or eNOS KO (8-week old) were further incubated with EPA
(25 mM) or AICAR (2 mM) in endothelial cell basal media (EBM)
for 24 h. After that, aortic rings were pre-constricted with
phenylephrine in organ chambers (PowerLab, AD Instruments,
Colorado Springs, CO). Endothelium-dependent and independent
vasodilation responses were determined in the presence of
acetylcholine (0.01 to 100 mM) and SNP (0.0001 to 1 mM),
respectively. When indicated, compound C (20 mM) were added
30 min prior to addition of EPA.
Statistics
Statistical comparisons of vasodilation were performed using a
two-way ANOVA. Intergroup differences were analyzed using
Bonferroni’s post test. Analysis of time-course studies was
performed with repeated measures ANOVA. All other results
were analyzed with one-way ANOVA. Values are expressed as
mean 6 SD. P values less than 0.05 were considered as significant.
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